BioPharma Dive April 30, 2024
By later this year, the company expects to be able to produce at least 50% more sellable doses of Zepbound and Mounjaro than it could in 2023.
Eli Lilly expects that, by the second half of this year, it will be able to manufacture at least 50% more sellable doses of the main ingredient in its GLP-1 medicines Zepbound and Mounjaro than it could during the same period last year.
The push to bolster the production capacity for the drugs, respectively sold for obesity and diabetes, is “the most ambitious expansion plan in our company’s history,” CEO David Ricks said on a first quarter earnings call with analysts Tuesday.
Delivering on that goal is imperative for Lilly, which on Tuesday...
Today's Sponsors
Today's Sponsor